

11/09/01

01-15-2002

Form PTO-1594 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002) Tab settings

REI 7



U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

101947556

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

The Immune Response Corporation

- Individual(s) Association General Partnership Limited Partnership Corporation-State of Delaware Other

Additional name(s) of conveying party(ies) attached? Yes No

3. Nature of conveyance:

- Assignment Merger Security Agreement Change of Name Other

Execution Date: November 9, 2001

2. Name and address of receiving party(ies)

Name: Kevin Kimberlin Partners, L.P.

Internal Address:

Street Address: 535 Madison Avenue

City: New York State: NY Zip: 10022

- Individual(s) citizenship Association General Partnership Limited Partnership Corporation-State of Delaware Other

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No (Designations must be a separate document from assignment) Additional name(s) & address(es) attached? Yes No

4. Application number(s) or registration number(s):

A. Trademark Application No.(s)

See Schedule 1

B. Trademark Registration No.(s)

See Schedule 2

Additional number(s) attached Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Edward P. Kelly

Internal Address: Kirkpatrick & Lockhart LLP

Street Address: 1251 Avenue of the Americas

City: New York State: NY Zip: 10020

6. Total number of applications and registrations involved:

6

7. Total fee (37 CFR 3.41): \$ 165.00

- Enclosed Authorized to be charged to deposit account

8. Deposit account number:

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Edward P. Kelly

Edward Kelly

11/9/01

Name of Person Signing

Signature

Date

Total number of pages including cover sheet, attachments, and document:

01/14/2002 6TON11 00000390 78018443

Mail documents to be recorded with required cover sheet information to: Commissioner of Patent & Trademarks, Box Assignments Washington, D.C. 20231

01 FC:481 02 FC:482

40.00 OP 125.00 OP

Schedule 1

Trademark Applications

<u>Mark</u>	<u>Serial No.</u>
Neurovac	78/018, 443
Neurovax	78/018, 363
Ravac	78/018, 710
Ravax	78/018, 708
Zorcell	78/004, 228

Schedule 2

Trademark Registrations

<u>Mark</u>	<u>Registration No.</u>
Remune	2,464,045

INTELLECTUAL PROPERTY SECURITY AGREEMENT

INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Agreement"), dated as of November 9, 2001, by and between The Immune Response Corporation, a Delaware corporation (the "Borrower"), and Kevin Kimberlin Partners, L.P., a Delaware limited partnership (the "Lender").

W I T N E S S E T H

WHEREAS, the Borrower and the Lender are parties to that certain Note Purchase Agreement of even date herewith (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Note Purchase Agreement"); and

WHEREAS, the Lender is willing to loan money to the Borrower as provided for in the Note Purchase Agreement, but only upon the condition, among others, that the Borrower shall have executed and delivered this Agreement, in order to secure the timely payment, performance and satisfaction of the obligations of the Borrower under the Notes, the Warrants, the Note Purchase Agreement and this Agreement (collectively, the "Obligations").

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

1. Defined Terms.

(a) Capitalized terms used herein shall have the meanings ascribed to such terms in the Note Purchase Agreement unless otherwise defined or limited herein.

(b) The words "hereof," "herein" and "hereunder" and words of like import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and Section references are to this Agreement unless otherwise specified.

(c) All terms defined in this Agreement in the singular shall have comparable meanings when used in the plural, and vice versa, unless otherwise specified herein.

(d) Any reference to the word "Borrower" in Sections 4, 5, 6 and 9 hereof shall be deemed to include any affiliate or subsidiary of the Borrower.

2. Incorporation of Premises. The premises set forth above are incorporated into this Agreement by this reference thereto and are made a part hereof.

3. Incorporation of the Note Purchase Agreement. The Note Purchase Agreement and the terms and provisions thereof are hereby incorporated herein in their entirety by this reference thereto.

4. Grant of Security Interest in Trademarks. To secure the complete and timely payment, performance and satisfaction of all of the Obligations, the Borrower hereby grants to the Lender a security interest in, as and by way of a first mortgage and security interest having priority over all other security interests, with power of sale to the fullest extent permitted by applicable law, all of the Borrower's now owned or otherwise existing and hereafter acquired or arising: (i) trademarks, trade names, registered trademarks, trademark applications, service marks, registered service marks and service mark applications, including, without limitation, the trademarks, trade names, registered trademarks, trademark applications, service marks, registered service marks and service mark applications listed on Schedule 4.8 attached to the Note Purchase Agreement and made a part hereof ("Schedule 4.8"), and (a) all renewals thereof, (b) all income, royalties, damages and payments now and hereafter due and/or payable under and with respect thereto, including, without limitation, payments under all licenses entered into in connection therewith and damages and payments for past or future infringements or dilutions thereof, (c) the right to sue for past, present and future infringements and dilutions thereof, (d) the goodwill of the Borrower's business symbolized by the foregoing and connected therewith and (e) all of the Borrower's rights corresponding thereto throughout the world (all of the foregoing trademarks, trade names, registered trademarks and trademark applications, service marks, registered service marks and service mark applications, together with the items described in clauses (a)-(e) in this Section 4, are hereinafter individually and/or collectively referred to as the "Trademarks"); and (ii) all proceeds of any and all of the foregoing, including, without limitation, license royalties and proceeds of infringement suits.

5. Grant of Security Interest in Patents. To secure the complete and timely payment, performance and satisfaction of all of the Obligations, the Borrower hereby grants to the Lender a security interest, as and by way of a first mortgage and security interest having priority over all other security interests, with power of sale to the fullest extent permitted by applicable law, in all of the Borrower's right, title and interest in and to the Borrower's now owned or otherwise existing and hereafter acquired or arising: (i) patents and patent applications, including, without limitation, the patents and patent applications listed on Schedule 4.8, and (a) all renewals, continuances and modifications thereof, (b) all income, royalties, damages and payments now and hereafter due and/or payable under and with respect thereto, including, without limitation, payments under all licenses entered into in connection therewith and damages and payments for past or future infringements, (c) the right to sue for past, present and future infringements, (d) the goodwill of the Borrower's business symbolized by the foregoing and connected therewith and (e) all of the Borrower's rights corresponding thereto throughout the world (all of the foregoing patents and patent applications, together with the items described in clauses (a)-(e) in this Section 5, are hereinafter individually and/or collectively referred to

as the "Patents"); and (ii) all proceeds of any and all of the foregoing, including, without limitation, license royalties and proceeds of infringement suits.

6. Grant of Security Interest in Trademark and Patent Licenses. To secure the complete and timely payment, performance and satisfaction of all of the Obligations, the Borrower hereby grants to the Lender a security interest, as and by way of a first mortgage and security interest having priority over all other security interests, with power of sale to the fullest extent permitted by applicable law, in all of the Borrower's right, title and interest in and to the Borrower's now owned or otherwise existing and hereafter acquired or arising rights under or interest in any license agreements with any other party, whether the Borrower is a licensee or licensor under any such license agreement, including, without limitation, license agreements listed on Schedule 4.8, and the right to use the foregoing in connection with the enforcement of the Lender's rights under the Note Purchase Agreement, including, without limitation, the right to prepare for sale and sell any and all inventory now or hereafter owned by the Borrower and now or hereafter covered by such licenses (all of the foregoing are hereinafter referred to collectively as the "Licenses"). Notwithstanding the foregoing provisions of this Section 6, the Licenses shall not include any license agreement in effect as of the date hereof that by its terms expressly prohibits the grant of the security contemplated by this Agreement; provided, however, that upon the termination of such prohibitions for any reason whatsoever, the provisions of this Section 6 shall be deemed to apply thereto automatically.

7. Power and Authority. The Borrower has the requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. The execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of the Borrower. This Agreement has been duly executed and delivered by the Borrower and is the valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, moratorium, insolvency, reorganization or other similar laws now or hereafter in effect generally affecting the enforcement of creditors' rights, specific performance, injunctive or other equitable remedies.

8. Title: Other Liens. Except for the security interests granted to the Lender pursuant to this Agreement, the Borrower owns each of the Trademarks, Patents and Licenses free and clear of any and all liens, claims or security or adverse interests thereon. No security agreement, financing statement or other public notice with respect to all or any of the Trademarks, Patents and Licenses is on file or of record in any public office, except as such as have been filed in favor of the Lender pursuant to this Agreement and the Note Purchase Agreement.

9. New Trademarks, Patents and Licenses. The Borrower represents warrants that (a) the Trademarks listed on Schedule 4.8 hereto include all of the trademarks, trade names, registered trademarks, trademark applications, service marks, registered service marks and service mark applications now owned or held by the Borrower, (b) the Patents listed on Schedule 4.8 hereto include all of the patents and

patent applications now owned or held by the Borrower, (c) the Licenses listed on Schedule 4.8 hereto include all of the license agreements under which the Borrower is the licensee or licensor and (d) no liens, claims or security or adverse interests in such Trademarks, Patents or Licenses have been granted by the Borrower to any person or entity other than the Lender. If, prior to the termination of this Agreement, the Borrower shall (i) obtain rights to or become entitled to the benefit of any new trademarks, trade names, registered trademarks, trademark applications, service marks, registered service marks or service mark applications, (ii) obtain rights to or become entitled to the benefit of any patent or patent application or any reissue, division, continuation, renewal, extension or continuation-in-part of any Patent or any improvement on any Patent, (iii) obtain rights to or become entitled to the benefit of any new license agreements, whether as licensee or licensor, or license renewals or (iv) enter into any new or amended license agreement, the provisions of Sections 4, 5 and 6 above shall automatically apply thereto (to the extent permitted by licensors under agreements in connection with the granting of such licenses). The Borrower shall give to the Lender prompt written notice of events described in clauses (i), (ii), (iii) and (iv) of the preceding sentence, and in any event within thirty (30) days, after the occurrence thereof. The Borrower hereby authorizes the Lender to modify this Agreement unilaterally (i) by amending Schedule 4.8 hereto to include any future trademarks, trade names, registered trademarks, trademark applications, service marks, registered service marks and service mark applications that are Trademarks under Section 4 above or under this Section 9, (ii) by amending Schedule 4.8 hereto to include any future patents and patent applications, that are Patents under Section above or under this Section 9, (iii) by amending Schedule 4.8 hereto to include any future license agreements that are Licenses under Section 6 above or under this Section 9 and (iv) by filing, in addition to and not in substitution for this Agreement, a duplicate original of this Agreement containing on Schedule 4.8 thereto, as the case may be, such future trademarks, tradenames, registered trademarks, trademark applications, service marks, registered service marks and service mark applications and containing on Schedule 4.8 thereto, as the case may be, such future patents and patent applications and containing on Schedule 4.8 thereto, as the case may be, such future license agreements.

10. Restrictions on Future Agreements. The Borrower will not enter into any agreement, including, without limitation, any license agreement, that is inconsistent with this Agreement or that would be reasonably likely to have a material adverse effect on the security interests held by the Lender pursuant to this Agreement, and the Borrower further agrees that it will not take any action, and will use its best efforts not to permit any action to be taken by others subject to its control, including, without limitation, licensees, or fail to take any action, that could be reasonably expected to, in any material respect, affect the validity or enforcement of the rights transferred to the Lender under this Agreement or the rights associated with the Trademarks, the Patents or the License.

11. Royalties. The Borrower hereby agrees that the use by the Lender of the Trademarks, Patents and Licenses as authorized hereunder in connection with the Lender's exercise of its rights and remedies under Section 20 hereof or pursuant to the

Note Purchase Agreement or any of the documents contemplated thereby (collectively, the "Loan Documents") shall be coextensive with the Borrower's rights thereunder and with respect thereto and without any liability for royalties or other related charges from the Lender to the Borrower.

12. Right to Inspect; Further Assignments and Security Interest; Future Indebtedness. The Lender may from time to time hereafter (at the Borrower's expense, but not more than once per calendar year absent an Event of Default or Nonpayment of Maintenance Fees (as defined in Section 14 hereof)) have access to, examine, audit, make copies and extracts from and inspect the Borrower's premises and examine the Borrower's books, records and operations relating to the Trademarks, Patents and Licenses. The Borrower agrees (i) not to sell or assign any of its interests in, or grant any license under the Trademarks or the Patents without the prior and express written consent of the Lender and/or (ii) not to sell or assign its respective interests in the Licenses without the prior and express written consent of the Lender. Without the prior and express written consent of the Lender, which consent shall not be unreasonably withheld, the Borrower hereby agrees that it shall not, while any of the Obligations are outstanding, incur, create or assume any indebtedness that is senior to the indebtedness evidenced by any of the Notes or grant any further security interest in the Trademarks, Patents and Licenses, and any modifications thereto pursuant to Section 9 hereof (the "Collateral"), even if such interest shall be junior to that of the Lender.

13. Nature and Continuation of the Lender's Security Interest; Termination of the Lender's Security Interest. This Agreement is made for collateral security purposes only. This Agreement shall create a continuing security interest in the Trademarks, Patents and Licenses and shall terminate only when the Obligations have been paid or performed in full and the Note Purchase Agreement has been terminated in accordance with its terms. When this Agreement has terminated, the Lender shall promptly execute and deliver to the Borrower, at the Borrower's expense, all termination statements and other instruments as may be necessary or proper to terminate the Lender's security interest in the Trademarks, Patents and Licenses, subject to any disposition thereof that may have been made by the Lender pursuant to this Agreement.

14. Duties of the Borrower. The Borrower shall (a) prosecute diligently any trademark application or service mark application that is part of the Trademarks pending as of the date hereof or hereafter until the termination of this Agreement, (b) prosecute diligently any patent application that is part of the Patents pending as of the date hereof or hereafter until the termination of this Agreement and (c) take all reasonable and necessary action to preserve and maintain all of the Borrower's rights in the Trademarks, the Patents and the Licenses, including, without limitation, the commencement of legal action for any infringement thereof by a third party that materially impairs the value of the Collateral; provided, however, that the Borrower shall not be obligated to take any of the foregoing actions unless the failure to take such actions would be reasonably likely to have a material adverse effect on either (x) the business, operations or condition of the Borrower or (y) the security interests of the Lender held pursuant to this Agreement. The

Borrower further agrees (i) not to abandon any Trademark, Patent or License without the prior written consent of the Lender and (ii) to use its best efforts to maintain in full force and effect the Trademarks, Patents and Licenses, including, without limitation, the timely payment of any maintenance fees for the Patents and/or the Trademarks; provided, however, that the Borrower shall not be obligated to take any of the foregoing actions unless the failure to take such actions would be reasonably likely to have a material adverse effect on either (x) the business, operations or condition of the Borrower or (y) the security interests of the Lender held pursuant to this Agreement.. Any expenses incurred in connection with the foregoing shall be borne by the Borrower. The Lender shall not have any duty with respect to the Trademarks, the Patents or the Licenses. Without limiting the generality of the foregoing, the Lender shall not be under any obligation to take any steps necessary to preserve rights in the Trademarks, the Patents or the Licenses against any other parties, but the Lender may do so, at its option, (x) if the Lender does not receive written confirmation of the payment of maintenance fees for the Patents and/or the Trademarks at least twenty (20) days prior to the due date for such payments, in which event the Lender may pay such fees ("Nonpayment of Maintenance Fees") or (y) from and after the occurrence and during the continuance of an Event of Default, and all expenses incurred in connection with clauses (x) and (y) of this Section 14 (including, without limitation, reasonable fees and expenses, including legal fees, of the Lender) shall be for the sole account of the Borrower and shall be added to the Obligations secured hereby.

15. Indemnification by the Borrower. The Borrower hereby agrees to indemnify and hold harmless and pay or reimburse the Lender for any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements (including reasonable attorneys' fees) of any kind whatsoever that may be imposed on, incurred by or asserted against the Lender in connection with, or in any way arising out of, any suits, proceedings or other actions, relating to any or all of the Trademarks, the Patents or the Licenses (including, without limitation, whether brought by the Borrower or any other Person, suits, proceedings or other actions in which an allegation of liability, strict or otherwise, is or may be made by any Person who alleges or may allege having suffered damages as a consequence of alleged improper, imprudent, reckless, negligent, willful, faulty, defective or substandard design, testing, specification, manufacturing supervision, manufacturing defect, manufacturing deficiency, publicity or advertisement or improper use, howsoever arising or by whomsoever caused, of any inventions disclosed and claimed in the Patents or any of them); unless with respect to any of the above, the Lender is judicially determined to have acted or failed to act with gross negligence or willful misconduct. The indemnification provisions in this Section 15 shall survive the termination of this Agreement.

16. The Lender's Right to Sue. From and after the occurrence and during the continuance of an Event of Default, the Lender shall have the right, but shall not be obligated, to bring suit in its own name to enforce the Trademarks, the Patents and the Licenses and, if the Lender shall commence any such suit, the Borrower shall, at the request of the Lender, do any and all lawful acts and execute any and all proper

documents reasonably required by the Lender in aid of such enforcement. The Borrower shall, upon demand, promptly reimburse the Lender for all costs and expenses incurred by the Lender in the exercise of its rights under this Section 16 (including, without limitation, reasonable fees and expenses, including legal fees, of the Lender).

17. Waivers. The Lender's failure, at any time or times hereafter, to require strict performance by the Borrower of any provision of this Agreement shall not waive, affect or diminish any right of the Lender thereafter to demand strict compliance and performance therewith nor shall any course of dealing between the Borrower and the Lender have such effect. No single or partial exercise of any right hereunder shall preclude any other or further exercise thereof or the exercise of any other right. None of the undertakings, agreements, warranties, covenants and representations of the Borrower contained in this Agreement shall be deemed to have been suspended or waived by the Lender unless such suspension or waiver is in writing signed by an officer of the Lender and directed to the Borrower and specifying such suspension or waiver.

18. Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but the provisions of this Agreement are severable and, if any clause or provision shall be held invalid and unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect only such clause or provision, or part hereof, in such jurisdiction and shall not in any manner affect such clause or provision in any other jurisdiction, or any other clause or provision of this Agreement in any jurisdiction.

19. Modification. Neither this Agreement nor any provision hereof may be altered, amended or modified in any way, except as specifically provided in Section 9 hereof or in a written instrument signed by the parties hereto.

20. Power of Attorney; Cumulative Remedies.

(a) The Borrower hereby irrevocably designates, constitutes and appoints the Lender (and all officers and agents of the Lender designated by the Lender in its sole and absolute discretion) as the Borrower's true and lawful attorney-in-fact, and authorizes the Lender and any of the Lender's designees, in the Borrower's or the Lender's name, upon the occurrence and during the continuation of an Event of Default to take any action and execute any instrument necessary or reasonably advisable to accomplish the purposes of this Agreement, including, without limitation, to (i) endorse the Borrower's name on all applications, documents, papers and instruments necessary or desirable for the Lender in the use of the Trademarks, the Patents or the Licenses, (ii) assign, pledge, convey or otherwise transfer title in or dispose of the Trademarks, the Patents or the Licenses to anyone, (iii) grant or issue any exclusive or nonexclusive license or sublicense under the Trademarks, the Patents or the Licenses to anyone and (iv) take any other actions with respect to the Trademarks, the Patents or the Licenses as the Lender deems in its best interest for the payment of the Obligations. The Borrower hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney is coupled with an interest and shall be irrevocable until

this Agreement is terminated. The Borrower acknowledges and agrees that this Agreement is not intended to limit or restrict in any way the rights and remedies of the Lender under the Note Purchase Agreement or any of the other Loan Documents, but rather is intended to facilitate the exercise of such rights and remedies.

(b) The Lender shall have, in addition to all other rights and remedies given it by the terms of this Agreement, all rights and remedies allowed by law and the rights and remedies of a secured party under the Uniform Commercial Code ("UCC") as enacted in any jurisdiction in which the Trademarks, the Patents or the Licenses may be located or deemed located. Upon the occurrence and during the continuance of an Event of Default and the election by the Lender to exercise any of its remedies under Section 9-504 or Section 9-505 of the UCC, or the equivalent remedy provisions under revised Article 9 of the UCC, as enacted in the governing jurisdiction, with respect to the Trademarks, the Patents or the Licenses, the Borrower agrees to assign, convey and otherwise transfer title in and to the Trademarks, the Patents and the Licenses, to the Lender or any transferee of the Lender and to execute and deliver to the Lender or any such transferee all such agreements, documents and instruments as may be necessary, in the Lender's sole discretion, to effect such assignment, conveyance and transfer. All of the Lender's rights and remedies with respect to the Trademarks, the Patents and the Licenses, whether established hereby, by the Note Purchase Agreement or by any other agreements or by law, shall be cumulative and may be exercised separately or concurrently. Notwithstanding anything set forth herein to the contrary, it is hereby expressly agreed that upon the occurrence and during the continuance of an Event of Default, the Lender may exercise any of the rights and remedies provided in this Agreement, the Note Purchase Agreement or any of the other Loan Documents. To the extent permitted by applicable law, the Borrower agrees that any notification of intended disposition of any of the Trademarks, the Patents or the Licenses required by law shall be deemed reasonably and properly given if given at least ten (10) days, if such notice is given by facsimile or twelve (12) days, if such notice is given by mail, before such disposition; provided, however, that the Lender may give any shorter notice that is commercially reasonable under the circumstances.

21. Successors and Assigns. This Agreement shall be binding upon the Borrower and its successors and permitted assigns, and shall inure to the benefit of the Lender and its nominees, successors and assigns. The Borrower's successors and assigns shall include, without limitation, a receiver or a trustee of the Borrower; provided, however, that the Borrower shall not voluntarily assign or transfer its rights or obligations hereunder without the Lender's prior written consent.

22. Governing Law. This Agreement shall be construed in accordance with and governed by the internal laws of the State of New York applicable to agreements made and to be wholly performed in New York.

23. Notices. All notices or other communications hereunder shall be given in the manner and to the addresses set forth in the Note Purchase Agreement.

24. Section Headings. The section headings herein are for convenience of reference only, and shall not affect in any way the interpretation of any of the provisions hereof.

25. Merger. This Agreement, together with the other Loan Documents, represents the final agreement of the Borrower and the Lender with respect to the matters contained herein and may not be contradicted by evidence of prior or contemporaneous agreements, or subsequent oral agreements between the Borrower and the Lender.

26. Effectiveness. This Agreement shall become effective on the date of the Note Purchase Agreement.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

THE IMMUNE RESPONSE CORPORATION,
a Delaware corporation

By: _____

Name: _____

Title: _____

KEVIN KIMBERLIN PARTNERS, L.P.,
a Delaware limited partnership

By: _____

Name: _____

Title: _____

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.


THE IMMUNE RESPONSE CORPORATION,
a Delaware corporation

By: _____

Name: _____

Title: _____

KEVIN KIMBERLIN PARTNERS, L.P.,
a Delaware limited partnership
By: KKD Management LLC, General Partner

By:  _____

Name: Kevin Kimberlin

Title: Member Manager

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

THE IMMUNE RESPONSE CORPORATION,
a Delaware corporation

By: [Signature]

Name: HOWARD SAMSON

Title: VP CFO

KEVIN KIMBERLIN PARTNERS, L.P.,
a Delaware limited partnership

By: _____

Name: _____

Title: _____

Immune Response Corporation

SCHEDULE 4.18(a)

Dkt. Ref.	Title	Inventor(s)	Serial No.	Filed	Country	Parent Docket(s)	Status	Ownership	Patents	Priority	Patent
8404	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	07/337,400	4/13/89	United States	CIP of 8003	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	5,112,735	5/12/92	Immune Response Corporation
2395	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	34588296	6/22/88	Japan	DIV of 8423	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	2752351	2/27/98	Immune Response Corporation
8334	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	US8802101	6/22/88	PCT	PCT of 8003	National Stage	Univ. of Vermont Exclusively Licensed to IRC			Immune Response Corporation
8335	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	569,971	6/22/88	Canada	NATL of 8334	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	1,305,912	8/4/92	Immune Response Corporation
8336	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	86810	6/22/88	Israel	NATL of 8334	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	86810	5/23/93	Immune Response Corporation
8421	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	20830/88	6/22/88	Australia	NATL of 8334	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	615464	2/18/92	Immune Response Corporation
8422	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	European Patent Convention	NATL of 8334	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0,321,554	12/22/93	Immune Response Corporation
8423	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	63-506111	6/22/88	Japan	NATL of 8334	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	2,625,191	4/11/97	Immune Response Corporation
9813	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	Austria	NATL of 8422	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0,321,554	12/22/93	Immune Response Corporation
9814	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	Belgium	NATL of 8422	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0,321,554	12/22/93	Immune Response Corporation
9815	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	Switzerland	NATL of 8422	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0,321,554	12/22/93	Immune Response Corporation
9815	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	Switzerland	NATL of 8422	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0,321,554	12/22/93	Immune Response Corporation

TRADEMARK
REEL: 002422 FRAME: 0829

Immune Response Corporation

9816	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	Germany	NATL of 8422	Patent Issued/Granted	Patent Issued	Univ. of Vermont Exclusively Licensed to IRC	0.321,554	12/22/93	Immune Response Corporation
9817	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	France	NATL of 8422	Patent Issued/Granted	Patent Issued	Univ. of Vermont Exclusively Licensed to IRC	0.321,554	12/22/93	Immune Response Corporation
9818	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	Great Britain	NATL of 8422	Patent Issued/Granted	Patent Issued	Univ. of Vermont Exclusively Licensed to IRC	0.321,554	12/22/93	Immune Response Corporation
9819	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	Italy	NATL of 8422	Patent Issued/Granted	Patent Issued	Univ. of Vermont Exclusively Licensed to IRC	0.321,554	12/22/93	Immune Response Corporation
9820	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	Luxembourg	NATL of 8422	Patent Issued/Granted	Patent Issued	Univ. of Vermont Exclusively Licensed to IRC	0.321,554	12/22/93	Immune Response Corporation
9821	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	Netherlands/Holland	NATL of 8422	Patent Issued/Granted	Patent Issued	Univ. of Vermont Exclusively Licensed to IRC	0.321,554	12/22/93	Immune Response Corporation
9822	DETECTION OF LYMPHOCYTE AMPLIFICATION	Albertini, Richard J.	88906441.6	6/22/88	Sweden	NATL of 8422	Patent Issued/Granted	Patent Issued	Univ. of Vermont Exclusively Licensed to IRC	0.321,554	12/22/93	Immune Response Corporation
9611	VACCINATION AND METHODS AGAINST MULTIPLE SCLEROSIS RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Smith, Lloyd M. Wilson, Darcy	08/055,006	4/29/93	United States	CIP of 8686	Pending	Patent Issued	IRC and Darcy Wilson			Immune Response Corporation
9704	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	08/103,418	8/6/93	United States	CONT of 9447	Patent Issued/Granted	Patent Issued	IRC	5,612,035	3/18/97	Immune Response Corporation
9791	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	08/146,454	11/1/93	United States	CONT of 9464	Patent Issued/Granted	Patent Issued	IRC	5,861,164	1/19/99	Immune Response Corporation
9830	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J. Brostoff, Steven W.	08/182,967	1/14/94	United States	CIP of 9107	Pending	Patent Issued	IRC			Immune Response Corporation
9892	PEPTIDES AND METHODS AGAINST DIABETES	Albertini, Richard J. Fala, Michael T. Brostoff, Steven W. Carlo, Dennis J.	08/195,963	2/14/94	United States	CIP of 8854	Patent Issued/Granted	Patent Issued	Univ. of Vermont Exclusively Licensed to IRC	6,113,903	9/5/00	Immune Response Corporation
1080	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Howell, Mark D. Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	08/276,776	7/18/94	United States	CONT of 9107	Patent Issued/Granted	Patent Issued	IRC	6,207,645	3/27/01	Immune Response Corporation

TRADE MARK
REF: 002422 FRAME: 0830

Immune Response Corporation

1448	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	08/302,102	9/7/94	United States	CONT of 9328	Pending	IRC	Immune Response Corporation
1197	ANTI-IDIOTYPE VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Howell, Mark D. Brostoff, Steven W. Carlo, Dennis J.	08/332,428	10/31/94	United States	CONT of 9556	Patent Issued/Granted	IRC	Immune Response Corporation
1254	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	08/376,049	1/20/95	United States	CONT of 9477	Patent Issued/Granted	IRC	Immune Response Corporation
1629	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	08/464,506	6/5/95	United States	DIV of 1254	Patent Issued/Granted	IRC	Immune Response Corporation
1631	PEPTIDES AND METHODS AGAINST PSORIASIS	Alberini, Richard J. Falla, Michael T. Howell, Mark D. Brostoff, Steven W. Carlo, Dennis J. Carlo, Dennis J. Brostoff, Steven W. Chang, Jennie	08/464,140	6/5/95	United States	CONT of 9892	pending	Univ. of Vermont Exclusively Licensed to IRC	Immune Response Corporation
1634	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J. Brostoff, Steven W. Chang, Jennie	08/462,471	6/5/95	United States	CONT of 9830	pending	IRC	Immune Response Corporation
1638	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	08/471,987	6/6/95	United States	DIV of 1080	pending	IRC	Immune Response Corporation
1639	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Howell, Mark D. Brostoff, Steven W. Carlo, Dennis J.	08/466,860	6/6/95	United States	DIV of 1080	Patent Issued/Granted	IRC	Immune Response Corporation
1640	METHOD OF PREVENTING THE PROLIFERATION OF VBETA14 OR VBETA17-EXPRESSING T CELLS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	08/471,209	6/6/95	United States	DIV of 1080	Patent Issued/Granted	IRC	Immune Response Corporation
1641	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	08/472,040	6/6/95	United States	CONT of 1080	Patent Issued/Granted	IRC	Immune Response Corporation
1134	OR TREATING AT CELL MEDIATED TREATING A T CELL MEDIATED	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	68926/94	3/21/90	Australia	DIV of 9040	Patent Issued/Granted	IRC	Immune Response Corporation
2430	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Howell, Mark D. Brostoff, Steven W. Carlo, Dennis J.	97/91236-4	3/21/90	Singapore	NATL of 8824	Patent Issued/Granted	IRC	Immune Response Corporation
3285	RESPONSES BY SPECIFIC T CELL POPULATIONS	Howell, Mark D. Brostoff, Steven W. Carlo, Dennis J.	90905821.6	3/21/90	Singapore	NATL of 8824	Patent Issued/Granted	IRC	Immune Response Corporation

TRADEMARK REEL 002422 FRAME: 0831

Immune Response Corporation

8677	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	900/01516	3/21/90	PCT	PCT of 8379	National Stage	National Stage	IRC				Immune Response Corporation
8824	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	European Patent Convention	NATL of 8677	Pending		IRC	0,463,101	1/12/94	Immune Response Corporation	
9040	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	5356790	3/21/90	Australia	NATL of 8677	Patent Issued/Granted		IRC	648753	5/5/94	Immune Response Corporation	
9042	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	2,046,909-9	3/21/90	Canada	NATL of 8677	Pending		IRC			Immune Response Corporation	
9043	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	914432	3/21/90	Finland	NATL of 8824	Pending		IRC			Immune Response Corporation	
9044	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	P-91-99	3/21/90	North Korea	NATL of 8677	Patent Issued/Granted		IRC	26745	10/21/93	Immune Response Corporation	
9047	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	701170/91	3/21/90	South Korea	NATL of 8677	Pending		IRC			Immune Response Corporation	
9048	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	5001756:14	3/21/90	Soviet Union	NATL of 8824	Patent Issued/Granted		IRC	2138512	9/27/99	Immune Response Corporation	
9835	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Austria	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation	
9836	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Belgium	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation	
9837	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Switzerland	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation	
9838	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Germany	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation	
9839	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Denmark	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation	

TRADE MARK REEL 002422 FRAME: 0832

Immune Response Corporation

9840	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Spain	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation
9841	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	France	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation
9842	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Great Britain	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation
9843	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Italy	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation
9844	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Luxembourg	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation
9845	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Netherlands/ Holland	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation
9846	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	90905821-6	3/21/90	Sweden	NATL of 8824	Patent Issued/Granted	Patent Issued	IRC	0,463,101	1/12/94	Immune Response Corporation
8676	VACCINATION AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	20013	3/22/90	Mexico	NATL of 8677	Patent Issued/Granted	Patent Issued	IRC	190785	12/16/98	Immune Response Corporation
1941	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	95250317.5	1/21/92	European Patent Convention	DIV of 9672	pending		IRC			Immune Response Corporation
2331	Vaccination and Methods Against Diseases Resulting from Pathogenic Responses by Specific T Cell Populations	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	70327/96	1/21/92	Australia	DIV of 9670	Patent Issued/Granted		IRC	694062	11/5/98	Immune Response Corporation
9180	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	US92/00482	1/21/92	PCT	PCT of 8854	National Stage		IRC			Immune Response Corporation
9671	AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	2,101,065	1/21/92	Canada	NATL of 9180	Pending		IRC			Immune Response Corporation
9673	AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	4-505397	1/21/92	Japan	NATL of 9180	Pending		IRC			Immune Response Corporation

TRADE MARK
KEEL 002422 FRAME: 0833

Immune Response Corporation

9674	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	932631	1/21/92	Norway	NATL of 9180	Pending	IRC			Immune Response Corporation
9455	VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS	Carlo, Dennis J. Howell, Mark D. Brostoff, Steven W.	US92/11159	12/21/92	PCT	PCT of 9107	National Stage	IRC			Immune Response Corporation
2607	Vaccination Against Diseases Resulting From Pathogenic Responses By Specific T Cell Populations	Carlo, Dennis J. Brostoff, Steven W. Howell, Mark D.	1101119	8/6/83	Brazil	NATL of 9704	Pending	IRC			Immune Response Corporation
1294	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J. Brostoff, Steven W. Chang, Jennie	95/00658	1/13/95	PCT	PCT of 9830	National Stage	IRC			Immune Response Corporation
2145	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J. Brostoff, Steven W. Chang, Jennie	17282/95	1/13/95	Australia	NATL of 1294	Patent Issued/Granted	IRC	697910	2/4/99	Immune Response Corporation
2147	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J.	2,179,280	1/13/95	Canada	NATL of 1294	Pending	IRC			Immune Response Corporation
2148	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J. Brostoff, Steven W. Chang, Jennie	95-1-91213.5	1/13/95	China	NATL of 1294	Pending	IRC			Immune Response Corporation
2149	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J.	95909258.6	1/13/95	European Patent Convention	NATL of 1294	pending	IRC			Immune Response Corporation
2150	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J.	962836	1/13/95	Finland	NATL of 1294	pending	IRC			Immune Response Corporation
2151	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J. Brostoff, Steven W. Chang, Jennie	7-519192	1/13/95	Japan	NATL of 1294	Pending	IRC			Immune Response Corporation
2152	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J. Brostoff, Steven W. Chang, Jennie	96-0577	1/13/95	North Korea	NATL of 1294	Patent Issued/Granted	IRC	31431	1/22/98	Immune Response Corporation
2153	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J.	703791/996	1/13/95	South Korea	NATL of 1294	pending	IRC			Immune Response Corporation
2154	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J.	96-02473	1/13/95	Mexico	NATL of 1294	pending	IRC			Immune Response Corporation
2155	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J.	962943	1/13/95	Norway	NATL of 1294	pending	IRC			Immune Response Corporation

TRADE MARK
TEL 002422
002422

Immune Response Corporation

2156	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J.	279987	1/13/95	New	NATL of 1294	Patent Issued/Granted	IRC	279987	4/20/00	Immune Response Corporation
4621	PEPTIDES AND METHODS AGAINST PSORIASIS	Carlo, Dennis J. Brostoff, Steven W. Chang, Jennie	2001-55930	1/13/95	Japan	DIV of 2151	Pending	IRC			Immune Response Corporation
1360	PEPTIDES AND METHODS AGAINST DIABETES	Albertini, Richard J. Falta, Michael T.	US9501572	2/10/95	PCT	PCT of 9892	National Stage	Univ. of Vermont Exclusively Licensed to IRC			Immune Response Corporation
2210	Peptides and Methods Against Diabetes	Albertini, Richard J. Falta, Michael T.	19128/95	2/10/95	Australia	NATL of 1360	Patent Lapsed	Univ. of Vermont Exclusively Licensed to IRC	690234	8/6/98	Immune Response Corporation
2211	Peptides and Methods Against Diabetes	Albertini, Richard J. Falta, Michael T.	2,182,978	2/10/95	Canada	NATL of 1360	pending	Univ. of Vermont Exclusively Licensed to IRC			Immune Response Corporation
2212	Peptides and Methods Against Diabetes	Albertini, Richard J. Falta, Michael T.	95911631.0-23	2/10/95	European Patent Convention	NATL of 1360	Pending	Univ. of Vermont Exclusively Licensed to IRC			Immune Response Corporation
2215	Peptides and Methods Against Diabetes	Albertini, Richard J. Falta, Michael T.	704434/1996	2/10/95	South Korea	NATL of 1360	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	10-280220	11/8/00	Immune Response Corporation

Family Name: Newell

102777004	METHODS AND PRODUCTS RELATED TO METABOLIC INTERACTIONS IN DISEASE		09/277,575	03/29/99	United States	claiming priority to Provisional 102777000 and 102777001	Pending	Univ. of Vermont Exclusively Licensed to IRC			Immune Response Corporation
102777004	METHODS AND PRODUCTS RELATED TO METABOLIC INTERACTIONS IN DISEASE		US99/06874	03/29/99	PCT	claiming priority to Provisional 102777000 and 102777001	Pending	Univ. of Vermont Exclusively Licensed to IRC			Immune Response Corporation
102777007	USE OF CD40 ENGAGEMENT TO ALTER T CELL RECEPTOR USAGE		09/470,494	12/22/99	United States	claiming priority to Provisional 102777005	Pending	Univ. of Vermont Exclusively Licensed to IRC			Immune Response Corporation
102777007	USE OF CD40 ENGAGEMENT ON T LYMPHOCYTES OR THYMOCYTES TO ALTER T CELL RECEPTOR USAGE		PCT/US99/30930	12/22/99	PCT	claiming priority to Provisional 102777005	Pending	Univ. of Vermont Exclusively Licensed to IRC			Immune Response Corporation
102777009	METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION IN THE PLASMA MEMBRANE		09/599,760	06/22/00	United States	claiming priority to Provisional 102777008	Pending	Univ. of Vermont Exclusively Licensed to IRC			Immune Response Corporation
102777009	METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION IN THE PLASMA MEMBRANE		PCT/US00/17245	06/22/00	PCT	claiming priority to Provisional 102777008	Pending	Univ. of Vermont Exclusively Licensed to IRC			Immune Response Corporation

TRADE MARK
REF ID: A602421
FRAME: 0835

Immune Response Corporation

102777011	AUTOLOGOUS ADOPTIVE IMMUNOTHERAPY WITH ANTIGEN-SPECIFIC PRIMED T CELLS OR B CELLS TO PROMOTE ANTIGEN-SPECIFIC IMMUNE RESPONSES WITH AN APPROPRIATE CYTOKINE BIAS	09/596,387	06/16/00	United States	claiming priority to Provisional 102777010	Pending	Univ. of Vermont Exclusively Licensed to IRC		
102777011 WO	AUTOLOGOUS ADOPTIVE IMMUNOTHERAPY WITH ANTIGEN-SPECIFIC PRIMED T CELLS OR B CELLS TO PROMOTE ANTIGEN-SPECIFIC IMMUNE RESPONSES WITH AN APPROPRIATE CYTOKINE BIAS	PCT/ US0016752	06/16/00	PCT	claiming priority to Provisional 102777010	Pending	Univ. of Vermont Exclusively Licensed to IRC		
102777012	METHODS AND PRODUCTS RELATED TO METABOLIC INTERACTIONS IN DISEASE	09/711,022	11/09/00	United States	Divisional of 102777004	Pending	Univ. of Vermont Exclusively Licensed to IRC		
102777013	METHODS FOR REGULATING CO-STIMULATORY MOLECULE EXPRESSION WITH REACTIVE OXYGEN	Not yet assigned	10/14/01	United States		Pending Provisional	Univ. of Vermont Exclusively Licensed to IRC		

TRADEMARK
REEL: 002422 FRAME: 0836

Family Name: Fusion Protein Cytokines

2442	Membrane-Bound Cytokine Compositions and Methods of Modulating an Immune Response	09/902,516	7/29/97	United States	NEW of	Patent Issued/Granted	IRC	5,891,432	4/6/99	Immune Response Corporation
3394	Membrane-Bound Cytokine Compositions and Methods of Modulating an Immune Response	09/201,931	12/1/98	United States	CONT of 2442	Pending	IRC			Immune Response Corporation
4735	Membrane-Bound Cytokine Compositions and Methods of Modulating an Immune Response	09/847,185	5/1/01	United States	CONT of 3394	Pending	IRC			Immune Response Corporation
3149	Membrane-Bound Cytokine Compositions and Methods of Modulating an Immune Response	PCT/US98/1562 2	7/27/98	PCT	PCT of 2442	National Stage	IRC			Immune Response Corporation
3902	Membrane-Bound Cytokine Compositions and Methods of Modulating an Immune Response	8597/98	7/27/98	Australia	NATL of 3149	Pending	IRC			Immune Response Corporation
3903	Membrane-Bound Cytokine Compositions and Methods of Modulating an Immune Response	2,297,747	7/27/98	Canada	NATL of 3149	Pending	IRC			Immune Response Corporation
3904	Membrane-Bound Cytokine Compositions and Methods of Modulating an Immune Response	98937204.0	7/27/98	European Patent Convention	NATL of 3149	Pending	IRC			Immune Response Corporation

Immune Response Corporation

3905	Membrane-Bound Cytokine Compositions and Methods of Modulating an Immune Response Using Same	Soo Hoo, William	2000-505285	7/27/98	Japan	NATL of 3149	Pending	IRC
4644	Membrane-Bound Cytokine Compositions and Methods of Modulating an Immune Response Using Same	Soo Hoo, William	00107786.5	7/27/98	Hong Kong	NATL of 3149	Pending	IRC

Family Name: HIV WITH ISS

4029	HIV Immunogenic Compositions and Methods	Moss, Ronald B	09/565,906	5/5/00	United States	B OF of 3528 B OF of 3693	Pending	IRC
------	--	----------------	------------	--------	---------------	------------------------------	---------	-----

4030	HIV Immunogenic Compositions and Methods	Moss, Ronald B	PCT/US00/1249	5/5/00	PCT	PCT of 3528 PCT of 3693	National Stage	IRC
------	--	----------------	---------------	--------	-----	----------------------------	----------------	-----

4989	HIV IMMUNOGENIC COMPOSITIONS AND METHODS	Moss, Ronald B	49929/00	5/5/00	Australia	NATL of 4030	Pending	IRC
------	--	----------------	----------	--------	-----------	--------------	---------	-----

4990	HIV IMMUNOGENIC COMPOSITIONS AND METHODS	Moss, Ronald B		5/5/00	Canada	NATL of 4030	Pending	IRC
------	--	----------------	--	--------	--------	--------------	---------	-----

4991	HIV IMMUNOGENIC COMPOSITIONS AND METHODS	Moss, Ronald B	00932163.9	5/5/00	European Patent Convention	NATL of 4030	Pending	IRC
------	--	----------------	------------	--------	----------------------------	--------------	---------	-----

4992	HIV IMMUNOGENIC COMPOSITIONS AND METHODS	Moss, Ronald B		5/5/00	Mexico	NATL of 4030	Pending	IRC
------	--	----------------	--	--------	--------	--------------	---------	-----

4993	HIV IMMUNOGENIC COMPOSITIONS AND METHODS	Moss, Ronald B		5/5/00	Brazil	NATL of 4030	Pending	IRC
------	--	----------------	--	--------	--------	--------------	---------	-----

4994	HIV IMMUNOGENIC COMPOSITIONS AND METHODS	Moss, Ronald B		5/5/00	South Africa	NATL of 4030	Pending	IRC
------	--	----------------	--	--------	--------------	--------------	---------	-----

4995	HIV IMMUNOGENIC COMPOSITIONS AND METHODS	Moss, Ronald B		5/5/00	OAPI (African Union)	NATL of 4030	Pending	IRC
------	--	----------------	--	--------	----------------------	--------------	---------	-----

4996	HIV IMMUNOGENIC COMPOSITIONS AND METHODS	Moss, Ronald B		5/5/00	ARIPO (African Regional Industrial Property Org)	NATL of 4030	Pending	IRC
------	--	----------------	--	--------	---	--------------	---------	-----

4997	HIV IMMUNOGENIC COMPOSITIONS AND METHODS	Moss, Ronald B		5/5/00	India	NATL of 4030	Pending	IRC
------	--	----------------	--	--------	-------	--------------	---------	-----

Immune Response Corporation

4998 HIV IMMUNOGENIC COMPOSITIONS AND METHODS Moss, Ronald B 5/5/00 Singapore NATL of 4030 Pending IRC Immune Response Corporation
 4999 HIV IMMUNOGENIC COMPOSITIONS AND METHODS Moss, Ronald B 5/5/00 Costa Rica NATL of 4030 Pending IRC Immune Response Corporation

Family Name: HRINDA

1963 PRODUCTION AND PURIFICATION OF RETROVIRAL PARTICLES USING OF TENTACLE ANION EXCHANGE Prior, Christopher P., Weber, David M., Gore, Richard S. 08/6/13,920 3/1/96 United States CONT of 1461 Patent Issued/Granted IRC Immune Response Corporation
 2531 Highly Efficient Production and Isolation of Viral Particles Utilizing Tentacle Anion Exchange Harter, James J., Prior, Christopher P., Weber, David M., Gore, Richard S. 08/8/42,702 4/15/97 United States CONT of 1963 Patent Issued/Granted IRC Immune Response Corporation

1495 HIGHLY EFFICIENT PRODUCTION AND ISOLATION OF VIRAL PARTICLES Harter, James J., Hrinida, Michael E., Bay, Pierre M., Gore, Richard S., Harter, James J., Irish, Thomas W., Mischelen, Jonathan J., Prior, Christopher P., Tarr, George C., Weber, David M. US95103668 3/22/95 PCT PCT of 1461 National IRC Immune Response Corporation

2253 Highly Efficient Production and Isolation of Viral Particles Hrinida, Michael E., Bay, Pierre M., Gore, Richard S., Harter, James J., Irish, Thomas W., Mischelen, Jonathan J., Prior, Christopher P., Tarr, George C., Weber, David M. 2,186,034 3/22/95 Canada NATL of 1465 Pending IRC Immune Response Corporation

2254 Highly Efficient Production and Isolation of Viral Particles Hrinida, Michael E., Irish, Thomas W., Mischelen, Jonathan J., Prior, Christopher P., Tarr, George C., Weber, David M., Bay, Pierre M., Gore, Richard S. 95914170.6 3/22/95 European Patent Convention NATL of 1465 Patent Issued/Granted IRC Immune Response Corporation

TRADEMARK
 REEL: 02422 FRAME: 0838

Immune Response Corporation

4065	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	7-524824	3/22/95	Japan	NATL of 1465	Pending	IRC	E 189697	2/9/00	Immune Response Corporation
4062	Highly Efficient Production and Isolation of Viral Particles	Hirnda, Michael E. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Austria	NATL of 2254	Patent Issued/Granted	IRC	E 189697	2/9/00	Immune Response Corporation
4063	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Belgium	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4064	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Switzerland	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4065	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Germany	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4066	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Denmark	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation

TRADEMARK

REEL: 00422 FRAME: 0839

Immune Response Corporation

4067	Highly Efficient Production and Isolation of Viral Particles	Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Spain	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4068	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	France	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4069	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	United Kingdom	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4070	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Greece	NATL of 2254	Patent Issued/Granted	IRC	3033268	2/9/00	Immune Response Corporation
4071	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Ireland	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4072	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Italy	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation

TRADE MARK
REEL: 002422 FRAME: 0840

Immune Response Corporation

4073	Highly Efficient Production and Isolation of Viral Particles	Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Luxembourg	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4074	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Monaco	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4075	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Netherlands/ Holland	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4076	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Portugal	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation
4077	Highly Efficient Production and Isolation of Viral Particles	Gore, Richard S. Harter, James J. Hirnda, Michael E. Irish, Thomas W. Mitschelen, Jonathan J. Prior, Christopher P. Tarr, George C. Weber, David M. Bay, Pierre M.	95914170.6	3/22/95	Sweden	NATL of 2254	Patent Issued/Granted	IRC	0751988	2/9/00	Immune Response Corporation

Family Name: Lymphocytes
 9713 METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES
 Albertini, Richard J.
 08/182,416
 1/14/94
 United
 NEW of
 Patent Issued/Granted
 Univ. of Vermont Exclusively Licensed to IRC
 5,482,837
 1/9/96
 Immune Response Corporation

TRADEMARK
REEL: 002122 FRAME: 0841

Immune Response Corporation

1295	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95/00434	1/13/95	PCT	PCT of 9713	National Stage	Univ. of Vermont Exclusively Licensed to IRC	0		Immune Response Corporation
2123	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	2-179,281	1/13/95	Canada	NATL of 1295	Pending	Univ. of Vermont Exclusively Licensed to IRC	0		Immune Response Corporation
2124	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	European Patent Convention	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2125	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	7-519120	1/13/95	Japan	NATL of 1295	Pending	Univ. of Vermont Exclusively Licensed to IRC	0		Immune Response Corporation
2648	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	Austria	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	AT E 154 949	7/2/97	Immune Response Corporation
2649	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	Belgium	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2650	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	Switzerland	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2651	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	Germany	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	69500393.3	7/2/97	Immune Response Corporation
2652	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	Denmark	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2653	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	Spain	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2654	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	France	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2655	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	United Kingdom	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2656	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	Greece	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2657	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	95907407.1	1/13/95	Ireland	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation

REEL 002422 FRAME 0842

Immune Response Corporation

2658	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	96907407.1	1/13/95	Italy	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2659	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	96907407.1	1/13/95	Luxembourg	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2660	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	96907407.1	1/13/95	Netherlands/Holland	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2661	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	96907407.1	1/13/95	Portugal	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/16/97	Immune Response Corporation
2662	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	96907407.1	1/13/95	Sweden	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation
2697	METHODS OF IDENTIFYING LYMPHOCYTES WITH MUTATOR PHENOTYPES	Albertini, Richard J.	96907407.1	1/13/95	Monaco	NATL of 1295	Patent Issued/Granted	Univ. of Vermont Exclusively Licensed to IRC	0 739 418	7/2/97	Immune Response Corporation

Family Name: Remune/STI

4580	METHODS FOR TREATING HIV-INFECTED INDIVIDUALS	Moss, Ronald B. Carlo, Dennis J.	60/264,476	01/26/01	United States		Pending				Immune Response Corporation
------	---	-------------------------------------	------------	----------	---------------	--	---------	--	--	--	-----------------------------

Family Name: SALK CARLO

9436	RETROVIRAL ANTIGENS	Carlo, Dennis J. Salk, Jonas	07/975,899	11/10/920	United States	CONT of 8051	Patent Issued/Granted		5,256,767	10/26/93	Immune Response Corporation
9953	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	08/233,508	04/26/94	United States	CONT of 9745	Patent Issued/Granted		5,653,725	12/29/98	Immune Response Corporation
1625	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	08/467,334	6/5/95	United States	CONT of 9953	Patent Issued/Granted		5,895,650	4/20/99	Immune Response Corporation
1675	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	08/467,302	6/5/95	United States	DIV of 9953	Patent Issued/Granted		6,017,543	1/25/00	Immune Response Corporation
1676	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	08/464,137	6/5/95	United States	DIV of 9953	Patent Issued/Granted		5,928,930	7/27/99	Immune Response Corporation
1679	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	08/469,739	6/5/95	United States	DIV of 9953	Patent Issued/Granted	IRC	5,885,578	3/23/99	Immune Response Corporation

TRADE MARK REF: 002422

Immune Response Corporation

1680	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	08/464,139	6/5/95	United States	DIV of 9953	Patent Issued/Granted	IRC	5,916,806	1/3/96	Immune Response Corporation
4109	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	09/545,966	4/10/00	United States	CONT of 1678	Pending	IRC			Immune Response Corporation
1485	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	Austria	NATL of 8414	Patent Issued/Granted	IRC	EP 0 317 622	1/3/96	Immune Response Corporation
1486	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	Belgium	NATL of 8414	Patent Issued/Granted	IRC	0 317 622	1/3/96	Immune Response Corporation
1487	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	Switzerland	NATL of 8414	Patent Issued/Granted	IRC	0 317 622	1/3/96	Immune Response Corporation
1488	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	Germany	NATL of 8414	Patent Issued/Granted	IRC	P 38 54 857.7-08	1/3/96	Immune Response Corporation
1489	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	France	NATL of 8414	Patent Issued/Granted	IRC	0 317 622	1/3/96	Immune Response Corporation
1490	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	Great Britain	NATL of 8414	Patent Issued/Granted	IRC	EP 0 317 622	1/3/96	Immune Response Corporation
1491	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	Italy	NATL of 8414	Patent Issued/Granted	IRC	EP 0 317 622	1/3/96	Immune Response Corporation
1492	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	Luxembourg	NATL of 8414	Patent Issued/Granted	IRC		1/3/96	Immune Response Corporation
1493	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	Netherlands/Holland	NATL of 8414	Patent Issued/Granted	IRC	EP 0 317 622	1/3/96	Immune Response Corporation
1494	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	Sweden	NATL of 8414	Patent Issued/Granted	IRC	0 317 622	1/3/96	Immune Response Corporation
8331	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	US88019656	6/9/88	PCT	PCT of 8301	National Stage	IRC			Immune Response Corporation
8332	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE (PREVENTIVE AND THERAPEUTIC AGENT FOR THE TREATMENT OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS))	Carlo, Dennis J. Salk, Jonas	569,026	6/9/88	Canada	NATL of 8331	Patent Issued/Granted	IRC	1,336,407	7/25/95	Immune Response Corporation

REEL: 002422 FRAME: 0844

Immune Response Corporation

8333	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	86675	6/9/88	Israel	NATL	of 8331	Patent Issued/Granted	IRC	86675	7/5/93	Immune Response Corporation
8411	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	19626/88	6/9/88	Australia				IRC	612383	11/29/91	Immune Response Corporation
8413	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	563/89	6/9/88	Denmark	NATL	of 8331	Pending	IRC			Immune Response Corporation
8414	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	88906347.5	6/9/88	European Patent Convention	NATL	of 8331	Patent Issued/Granted	IRC	1/3/96	0 317 622	Immune Response Corporation
8415	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	89-0603	6/9/88	Finland	NATL	of 8331	Patent Issued/Granted	IRC	95871	4/10/96	Immune Response Corporation
8416	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	63-505484	6/9/88	Japan	NATL	of 8331	Patent Issued/Granted	IRC	1985173	10/25/95	Immune Response Corporation
8417	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	89/0565	6/9/88	Norway	NATL	of 8331	Patent Issued/Granted	IRC	175,846	12/21/94	Immune Response Corporation
8418	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	59525	6/9/88	OAPJ (African Union)	NATL	of 8331	Patent Issued/Granted	IRC	9037	3/31/91	Immune Response Corporation
8419	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	US88/01955	6/9/88	Sudan	NATL	of 8331	Patent Issued/Granted	IRC	PCT/SD/218	9/10/98	Immune Response Corporation
8420	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	4613460.14	6/9/88	Soviet Union	NATL	of 8331	Patent Issued/Granted	IRC	1,837,890	10/13/82	Immune Response Corporation
9509	ANTIBODIES REACTIVE WITH ONE OR MORE RETROVIRAL PROTEINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME	Carlo, Dennis J. Salk, Jonas	104.337	6/9/88	Israel	DIV	of 8331	Patent Issued/Granted	IRC	104,337	8/31/94	Immune Response Corporation
9512	ANT-IDIOTYPE ANTIBODIES	Carlo, Dennis J. Salk, Jonas	104.340	6/9/88	Israel	DIV	of 8331	Patent Issued/Granted	IRC	104,340	9/25/94	Immune Response Corporation
9680	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	4613460.27	6/9/88	Belarus	EXT	of 8420	Patent Issued/Granted	IRC	1253	7/23/93	Immune Response Corporation
9385	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	50522305	5/14/92	Soviet Union	DIV	of 8420	Patent Issued/Granted	IRC	2 111 010	5/20/98	Immune Response Corporation

REEL: 002422 FRAME: 0845

Immune Response Corporation

9688	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	93 004 572	5/14/92	Ukraine	EXT	of 9385	Patent Issued/Granted	IRC	27716	10/16/00	Immune Response Corporation
2606	Retroviral Antigens	Carlo, Dennis J. Salk, Jonas	1101124	11/10/92	Brazil	NATL	of 9436	Pending	IRC			Immune Response Corporation
9510	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	104.338	1/7/93	Israel	DIV	of 8331	Patent Issued/Granted	IRC	104.338	2/28/96	Immune Response Corporation
9511	A METHOD FOR THE EXTRACORPOREAL REMOVAL OF ANTIBODIES	Carlo, Dennis J. Salk, Jonas	104.339	1/7/93	Israel	DIV	of 8331	Patent Issued/Granted	IRC	104.339	4/25/95	Immune Response Corporation
9686	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	463	7/2/93	Belarus	EXT	of 8420	Pending	IRC			Immune Response Corporation
9682	PREVENTION AND TREATMENT OF RETROVIRAL DISEASE	Carlo, Dennis J. Salk, Jonas	96240071	4/13/94	Ukraine	DIV	of 8420	Pending	IRC			Immune Response Corporation

Family Name: TCR Combinations

2406	Combinations of TCR Peptides For Inhibiting T Cell Mediated Diseases	Carlo, Dennis J. Brostoff, Steven W. Howell, Mark D.			United States	NEW	of	Propose	IRC			Immune Response Corporation
------	--	--	--	--	---------------	-----	----	---------	-----	--	--	-----------------------------

Family Name: Vandenberg

5034	T CELL RECEPTOR PEPTIDES AS THERAPEUTICS FOR IMMUNE-RELATED DISEASE	Vandenberg, Arthur A.			United States	CIP	of 3963	Proposed	IRC	5,614,192	3/25/97	Immune Response Corporation
3967	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vandenberg, Arthur A.	08059,020	3/16/93	United States	CONT	of 3968	Patent Issued/Granted	IRC			Immune Response Corporation
3963	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vandenberg, Arthur A.	08476,552	6/6/95	United States	DIV	of 3967	Pending	IRC			Immune Response Corporation
4106	TCR V BETA 5 PEPTIDES	Vandenberg, Arthur A.	08476,405	6/7/95	United States	CIP	of 3967	Patent Issued/Granted	IRC	5,776,459	7/7/98	Immune Response Corporation
3969	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vandenberg, Arthur A.	US92/04492	6/1/92	PCT	PCT	of 3968	Stage National				Immune Response Corporation
3969	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vandenberg, Arthur A.	US92/04492	6/1/92	PCT	PCT	of PCT of 3968	National Stage	IRC			Immune Response Corporation

TRADE MARK REF: 00242

Immune Response Corporation

3972	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912864.3	6/1/92	European Patent Convention	NATL	of 3969	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corpora
3973	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	500563/93	6/1/92	Japan	NATL	of 3969	Pending	IRC			Immune Response Corpora
3974	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	2,110,055	6/1/92	Canada	NATL	of 3969	Pending	IRC			Immune Response Corpora
3975	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	21,472/92	6/1/92	Australia	NATL	of 3969	Patent Issued/Granted	IRC	674,494	5/26/97	Immune Response Corpora
3976	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	P934320	6/1/92	Norway	NATL	of 3969	Pending	IRC			Immune Response Corpora
4034	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	10-2000-70021	6/1/92	South Korea	DIV	of 3970	Patent Issued/Granted	IRC	304042	7/18/01	Immune Response Corpora
4084	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912864.3	6/1/92	Austria	NATL	of 3972	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corpora
4085	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912864.3	6/1/92	Belgium	NATL	of 3972	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corpora
4086	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912864.3	6/1/92	Switzerland	NATL	of 3972	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corpora
4087	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912864.3	6/1/92	Denmark	NATL	of 3972	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corpora
4088	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912864.3	6/1/92	Germany	NATL	of 3972	Patent Issued/Granted	IRC	DE6923061 2 T2	1/26/00	Immune Response Corpora
4089	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912864.3	6/1/92	Spain	NATL	of 3972	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corpora
4090	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912864.3	6/1/92	France	NATL	of 3972	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corpora
4091	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912864.3	6/1/92	United Kingdom	NATL	of 3972	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corpora



Immune Response Corporation

4092	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912684.3	6/1/92	Greece	NATL	of	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corporation
4093	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912684.3	6/1/92	Italy	NATL	of	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corporation
4094	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912684.3	6/1/92	Netherlands/Holland	NATL	of	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corporation
4095	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	92912684.3	6/1/92	Sweden	NATL	of	Patent Issued/Granted	IRC	0587735	1/26/00	Immune Response Corporation

Family Name: Vanderbark-2

3978	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	US90/04085	7/1/90	PCT	PCT	of PCT	National Stage	IRC			Immune Response Corporation
3978	T Cell Receptor Peptides as Therapeutics for Immune-Related Disease	Vanderbark, Arthur A.	US90/04085	7/1/90	PCT	PCT	of PCT	National Stage	IRC			Immune Response Corporation
3979	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	European Patent Convention	NATL	of	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
3980	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	60,485/90	7/1/90	Australia	NATL	of	Patent Issued/Granted	IRC	652,540	1/10/95	Immune Response Corporation
3981	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	510609/90	7/1/90	Japan	NATL	of	Patent Issued/Granted	IRC	3072330	6/2/00	Immune Response Corporation
3982	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	P920252	7/1/90	Norway	NATL	of	Pending	IRC			Immune Response Corporation
3983	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	2,064,077.4	7/1/90	Canada	NATL	of	Pending	IRC			Immune Response Corporation
3984	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	92-700152	7/1/90	South Korea	NATL	of	Patent Issued/Granted	IRC	216097	5/27/99	Immune Response Corporation
3986	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	234586	7/1/90	New Zealand	FOR APP of	Patent Issued/Granted	IRC	234586	6/14/93	Immune Response Corporation	
3987	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	95125	7/1/90	Israel	FOR APP of	Patent Issued/Granted	IRC	95125	11/1/95	Immune Response Corporation	

REEL: 002422 FRAME: 0848

Immune Response Corporation

4250	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Austria	FOR APP of 3978	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4251	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Belgium	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4252	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Switzerland	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4253	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Germany	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4254	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Denmark	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4255	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Spain	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4256	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	France	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4257	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Great Britain	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4258	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Italy	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4259	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Luxembourg	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4260	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Netherlands/Holland	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation
4261	T Cell Receptor Peptides as Therapeutics for Autoimmune and Malignant Disease	Vanderbark, Arthur A.	90911332.6	7/1/90	Sweden	NATL of 3979	Patent Issued/Granted	IRC	0552142	1/7/98	Immune Response Corporation

Family Name: Vanderbark-3

4734 Methods of Identifying and Monitoring Disease-Associated T Cells Vanderbark, Arthur A. 09/853,830 5/10/01 United States B OF of 4733 Pending IRC

TRADE MARK REF: 002422 FRAME: 0849

Immune Response Corporation

Client: Sidney-Kimmel Cancer Center (SKCC)

Family Name: FAKHRAI
1032 COMPOSITIONS AND METHODS FOR ENHANCED TUMOR CELL IMMUNITY IN VIVO Fakhrai, Habib
Dorigo, Oliver
Sobol, Robert E. 08/27/6,694 7/18/94 United States NEW of Patent Issued/Granted SKCC Exclusively Licensed to IRC; Sublicensed to Novartis 5,772,995 6/30/98

2888 Compositions and Methods for Enhanced Tumor Cell Immunity In Vivo Fakhrai, Habib
Dorigo, Oliver
Sobol, Robert E. 08/968,986 11/12/97 United States CONT of Patent Issued/Granted SKCC Exclusively Licensed to IRC 6,120,763 9/19/00

4038 Compositions and Methods for Enhanced Tumor Cell Immunity In Vivo Dorigo, Oliver
Sobol, Robert E. 09/516,737 3/1/00 United States CONT of Pending SKCC Exclusively Licensed to IRC 711,730 10/21/99

1755 COMPOSITIONS AND METHODS FOR ENHANCED TUMOR CELL IMMUNITY IN VIVO Fakhrai, Habib
Dorigo, Oliver
Sobol, Robert E. US95/09198 7/18/95 PCT of National Stage SKCC Exclusively Licensed to IRC 711,730 10/21/99

2412 Compositions and Methods For Enhanced Tumor Cell Immunity In Vivo Fakhrai, Habib
Dorigo, Oliver
Sobol, Robert E. 3217895 7/18/95 Australia NATL of Patent Issued/Granted SKCC Exclusively Licensed to IRC 711,730 10/21/99

2413 Compositions and Methods For Enhanced Tumor Cell Immunity In Vivo Fakhrai, Habib
Dorigo, Oliver
Sobol, Robert E. 2,195,334 7/18/95 Canada NATL of Pending SKCC Exclusively Licensed to IRC 711,730 10/21/99

2414 Compositions and Methods For Enhanced Tumor Cell Immunity In Vivo Fakhrai, Habib
Dorigo, Oliver
Sobol, Robert E. 95928099.1 7/18/95 European Patent Convention NATL of Pending SKCC Exclusively Licensed to IRC 711,730 10/21/99

2415 Compositions and Methods For Enhanced Tumor Cell Immunity In Vivo Fakhrai, Habib
Dorigo, Oliver
Sobol, Robert E. 8-505255 7/18/95 Japan NATL of Pending SKCC Exclusively Licensed to IRC 711,730 10/21/99

Family Name: HAPLOTYPE
1146 HAPLOTYPE-MATCHED CYTOKINE SECRETING CELLS AND METHODS OF USING TO STIMULATE IMMUNE RESPONSE AGAINST A TUMOR LOCATED IN THE CENTRAL NERVOUS SYSTEM OF A PATIENT Fakhrai, Habib
Rojston, Ivor K.
Sobol, Robert E. US94/10217 9/6/94 PCT of National Stage SKCC Exclusively Licensed to IRC 5,681,562 10/28/97

Family Name: IMMUNOTHERAPY
08/952,990 Friedmann, Theodore
Rojston, Ivor K.
Sobol, Robert E. 12/9/94 United States CONT of Response/Office Issued/Granted SKCC Exclusively Licensed to IRC 5,674,486 10/7/97

1584 CANCER IMMUNOTHERAPY WITH CARRIER CELLS Gage, Fred H.
Sobol, Robert E.
Rojston, Ivor K.
Gage, Fred H.
Friedmann, Theodore 08/473,123 6/6/95 United States CONT of Issued/Granted SKCC Exclusively Licensed to IRC 5,674,486 10/7/97

Immune Response Corporation

2550	CANCER IMMUNOTHERAPY	Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	08/84,292	4/29/97	United States	CONT	of 1584	Pending	SKCC Exclusively Licensed to IRC	E 188125	12/29/99
3921	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	92922731.2	10/23/92	Austria	NATL	of 9946	Granted Issued/Granted	SKCC Exclusively Licensed to IRC	E 188125	12/29/99
3922	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	92922731.2	10/23/92	Belgium	NATL	of 9946	Granted Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3923	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	92922731.2	10/23/92	Greece	NATL	of 9946	Granted Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3924	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	92922731.2	10/23/92	Ireland	NATL	of 9946	Granted Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3925	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	92922731.2	10/23/92	Italy	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3926	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	92922731.2	10/23/92	Luxembourg	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3927	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	92922731.2	10/23/92	Spain	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3928	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	92922731.2	10/23/92	Sweden	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3929	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	92922731.2	10/23/92	Switzerland	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3930	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H.	92922731.2	10/23/92	Germany	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99

Immune Response Corporation

3928	LYMPHOKINE GENE THERAPY OF CANCER	Sobol, Robert E. Royston, Ivor K. Gage, Fred H. Friedmann, Theodore	92922731.2	10/23/92	Sweden	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3931	LYMPHOKINE GENE THERAPY OF CANCER	Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H. Friedmann, Theodore	92922731.2	10/23/92	France	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3932	LYMPHOKINE GENE THERAPY OF CANCER	Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H. Friedmann, Theodore	92922731.2	10/23/92	Monaco	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3933	LYMPHOKINE GENE THERAPY OF CANCER	Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H. Friedmann, Theodore	92922731.2	10/23/92	Denmark	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3934	LYMPHOKINE GENE THERAPY OF CANCER	Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H. Friedmann, Theodore	92922731.2	10/23/92	Netherlands/ Holland	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
3935	LYMPHOKINE GENE THERAPY OF CANCER	Fakhrai, Habib Sobol, Robert E. Royston, Ivor K. Gage, Fred H. Friedmann, Theodore	92922731.2	10/23/92	Great Britain	NATL	of 9946	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
9437	LYMPHOKINE GENE THERAPY OF CANCER	Fakhrai, Habib Friedmann, Theodore Gage, Fred H. Royston, Ivor K. Sobol, Robert E.	PCT/US920899 9	10/23/92	PCT	PCT	of 9117	National Stage	SKCC Exclusively Licensed to IRC		
9945	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Gage, Fred H. Royston, Ivor K. Sobol, Robert E.	2,121,127	10/23/92	Canada	NATL	of 9437	Pending	SKCC Exclusively Licensed to IRC		
9946	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Gage, Fred H. Royston, Ivor K. Sobol, Robert E.	92922731.2	10/23/92	European Patent Convention	NATL	of 9437	Patent Issued/Granted	SKCC Exclusively Licensed to IRC	0668781	12/29/99
9947	LYMPHOKINE GENE THERAPY OF CANCER	Friedmann, Theodore Gage, Fred H. Royston, Ivor K. Sobol, Robert E.	5-507903	10/23/92	Japan	NATL	of 9437	Pending	SKCC Exclusively Licensed to IRC		

Client: University of California, Los Angeles

Family Name: Combined Radiotherapy

Immune Response Corporation

1932	TUMOR RADIOSENSITIZATION USING GENE THERAPY	McBride, William H.	08/597,524	2/2/96	United States	NEW	of	Patent Issued/Granted	UCLA Licensed to IRC; Sublicensed to Genstar	6,051,218	4/18/00
4032	TUMOR RADIOSENSITIZATION USING GENE THERAPY	McBride, William H.	09/535,654	3/24/00	United States	CONT	of 1932	Pending	Licensed to IRC; Sublicensed to Genstar		
2407	Combined Radiotherapy and Immunotherapy to Treat	McBride, William H.	US97/01465	1/31/97	PCT	PCT	of 1932	National Stage	UCLA Licensed to IRC; Sublicensed to Genstar		
3204	Combined Radiotherapy and Immunotherapy to Treat Cancer	McBride, William H.	2,244,841	1/31/97	Canada	NATL	of 2407	Pending	UCLA Licensed to IRC; Sublicensed to Genstar		
3205	Combined Radiotherapy and Immunotherapy to Treat Cancer	McBride, William H.	97904085.4	1/31/97	European Patent Convention	NATL	of 2407	Pending	UCLA Licensed to IRC; Sublicensed to Genstar		
2206	Combined Radiotherapy and Immunotherapy to Treat Cancer	McBride, William H.	9-527808	1/31/97	Japan	NATL	of 2407	Pending	UCLA Licensed to IRC; Sublicensed to Genstar		
3896	Combined Radiotherapy and Immunotherapy to Treat Cancer	McBride, William H.	99104559.7	1/31/97	Hong Kong	NATL	of 2407	Pending	UCLA Licensed to IRC; Sublicensed to Genstar		

Client: Sidney-Kimmel Cancer Center

Family Name: TUMOR CELL VACCINE

4581	Genetically Engineered Tumor Cell Vaccines	Sobol, Robert E. Shawler, Daniel Bartholomew, Richard M. Carlo, Dennis J. Gold, Daniel P. Sobol, Robert E.	09/772,102	1/26/01	United States	B OF	of 3832	Pending	IRC and SKCC
4582	Genetically Engineered Tumor Cell Vaccines		PCT/US01/0273 1	1/26/01	PCT	PCT	of 3832 of 3990	Pending	IRC and SKCC

Immune Response Corporation

Serial/ Patent #	Ownership	Title	Filing/Issue Date	Status	Pending
TTL-039CP3CN	U. of CT Licensed to IRC	Targeted Delivery of Poly- or Oligonucleotides to Cells	06/02/95 02/29/00	Patent	
TTL-117CN	U. of CT Licensed to IRC	Carrier System and Method for the Introduction of Genes Into Mammalian Cells	04/02/90 - 11/24/92	Patent	
TTL-117CN3	U. of CT Licensed to IRC	Carrier System and Method for the Introduction of Genes Into Mammalian Cells	01/04/95 06/03/97	Patent	
TTL-117CN4	U. of CT Licensed to IRC	Soluble Molecular Complex For The Introduction Of Genes Into Mammalian Cells	07/31/96 02/23/99	Patent	
TTL-138	IR. C.	Antisense Constructs Directed Against Viral Post-Transcriptional Regulatory Sequences	3/11/96 12/01/98	Patent	
TTL-139	IR. C.	Use Of Viral Cis-Acting Post-Transcriptional Regulatory Sequences Containing Near- Consensus Splice Sites	3/11/96 4/28/98	Patent	
TTL-141	IR. C.	Method Of Preparing Polynucleotide-Carrier Complexes For Delivery To Cells	2/21/96 11/30/99	Patent	
TTL-143CP	IR. C.	Targeted Delivery Of Genes Encoding Interferon	3/17/97 05/30/00	Patent	
TTL-143CPCN	IR. C.	Targeted Delivery Of Genes Encoding Interferon	08/23/99	Pending	X
TTL-180	IR. C.	Novel Vectors and Genes Exhibiting Increased Expression	12/04/98	Pending	X
TTL-180DV	IR. C.	Novel Vectors and Genes Exhibiting Increased Expression	09/55/368	Pending	X

Immune Response Corporation

	Countries	Ownership	Serial/Patent No.	Title	Filing/Issue Date	Status	Pending
TTI-027CA	Canada	U. of CT and TargetTech Licensed to IRC	2,103,064	Targeted Delivery of Genes Encoding Immunogenic Proteins	05/14/92	Pending	X
TTI-027CH	Switzerland	U. of CT and TargetTech Licensed to IRC	92 91 3964.0 Patent No. 0584279	Targeted Delivery of Genes Encoding Immunogenic Proteins	05/14/92 03/14/01	Patent	X
TTI-027DE	Germany	U. of CT and TargetTech Licensed to IRC	92 91 3964.0 Patent No. 692 31 736 8 08	Targeted Delivery of Genes Encoding Immunogenic Proteins	05/14/92 03/14/01	Patent	X
TTI-027DK	Denmark	U. of CT and TargetTech Licensed to IRC	92 91 3964.0 Patent No. 0584279	Targeted Delivery of Genes Encoding Immunogenic Proteins	05/14/92 03/14/01	Patent	X
TTI-027ES	Spain	U. of CT and TargetTech Licensed to IRC	92 91 3964.0 Patent No. 0584279	Targeted Delivery of Genes Encoding Immunogenic Proteins	05/14/92 03/14/01	Patent	X
TTI-027FR	France	U. of CT and TargetTech Licensed to IRC	92 91 3964.0 Patent No. 0584279	Targeted Delivery of Genes Encoding Immunogenic Proteins	05/14/92 03/14/01	Patent	X
TTI-027GB	Great Britain	U. of CT and TargetTech Licensed to IRC	92 91 3964.0 Patent No. 0584279	Targeted Delivery of Genes Encoding Immunogenic Proteins	05/14/92 03/14/01	Patent	X
TTI-027IT	Italy	U. of CT and TargetTech Licensed to IRC	92 91 3964.0 Patent No. 0584279	Targeted Delivery of Genes Encoding Immunogenic Proteins	05/14/92 03/14/01	Patent	X
TTI-027NL	Netherlands	U. of CT and TargetTech Licensed to IRC	92 91 3964.0 Patent No. 0584279	Targeted Delivery of Genes Encoding Immunogenic Proteins	05/14/92 03/14/01	Patent	X

Immune Response Corporation

TTL-027SE	Sweden	U. of CT and TargetTech Licensed to IRC	92 91 3964.0 Patent No. 0584279	Targeted Delivery of Genes Encoding Immunogenic Proteins	05/14/92 03/14/01	Patent	X
TTL-039EP	EPO	U. of CT Licensed to IRC	92 92 0863.5 Publ. No. 0666923	Targeted Delivery of Poly- or Oligonucleotides to Cells	09/04/92 Publ. Date 08/16/95	Pending	X
TTL-039KR	So. Korea	U. of CT Licensed to IRC	(PCT)700741/94 252547	Targeted Delivery of Poly- or Oligonucleotides to Cells	09/04/92 01/19/00	Patent	X
TTL-045CPJP	Japan	TargetTech Licensed to IRC	07-518699 Publ. No. 9-510696	Hepatocyte-Targeted Drug Conjugates	01/11/95 Publ. Date: 10/28/97	Pending	X
TTL-096CA	Canada	TargetTech and U. of CT Licensed to IRC	2159916	Targeted Delivery of Genes Encoding Antisense Polynucleotides	10/4/95	Pending	X
TTL-096EP	Europe	TargetTech and U. of CT Licensed to IRC	94 91 2389.7 0693130	Targeted Delivery of Genes Encoding Antisense Polynucleotides	09/28/95 01/24/96	Pending	X
TTL-117JP (formerly UCI-001JP)	Japan	U. of CT Licensed to IRC	23633/88 Patent No. 2731844	Carrier System and Method for the Introduction of Genes Into Mammalian Cells	02/03/88 12/26/97	Patent	
TTL-139AU	PCT	IRC.C.	20717/97 Patent No. 715567	Use Of Viral Cis-Acting Post-Transcriptional Regulatory Sequences Containing Near-Consensus Splice Sites	03/10/97 05/18/00	Patent	
TTL-139CA	Canada	IRC.C.	2,248,539	Use Of Viral Cis-Acting Post-Transcriptional Regulatory Sequences Containing Near-Consensus Splice Sites	03/10/97	Pending	X
TTL-139EP	EPO	IRC.C.	97 90 8930.7 Publ. No. 0888451	Use Of Viral Cis-Acting Post-Transcriptional Regulatory Sequences Containing Near-Consensus Splice Sites	03/10/97 01/07/99	Pending	X

Immune Response Corporation

TTI-139HK	Hong Kong	I.R.C.	99102022.0	Use Of Viral Cis-Acting Post-Transcriptional Regulatory Sequences Containing Near-Consensus Splice Sites	03/10/97	Pending	X
TTI-139JP	Japan	I.R.C.	09-532696	Use Of Viral Cis-Acting Post-Transcriptional Regulatory Sequences Containing Near-Consensus Splice Sites	03/10/97	Pending	X
TTI-143CPAU	Australia	I.R.C.	23223/97 Patent No. 728146	Targeted Delivery Of Genes Encoding Interferon	03/14/97 04/19/01	Patent	X
TTI-143CPCA	Canada	I.R.C.	2248538	Targeted Delivery Of Genes Encoding Interferon	03/14/97	Pending	X
TTI-143CPEP	Europe	I.R.C.	97 91 5916.7 Publ. No. 0904373	Targeted Delivery Of Genes Encoding Interferon	03/14/97 Publ. Date 03/31/99	Pending	X
TTI-143CPHK	Hong Kong	I.R.C.	99104212.6	Targeted Delivery Of Genes Encoding Interferon	9/28/99	Pending	X
TTI-143CPJP	Japan	I.R.C.	09-532785	Targeted Delivery Of Genes Encoding Interferon	03/14/97	Pending	X
TTI-180AU	Australia	I.R.C.	16121/99 Publ. No.: 735,763	Novel Vectors and Genes Exhibiting Increased Expression	11/25/98 Publ. Date: 07/12/01	Pending	X
TTI-180CA	Canada	I.R.C.	2,312,291	Novel Vectors and Genes Exhibiting Increased Expression	11/25/98	Pending	X
TTI-180EP	Europe	I.R.C.	98 96 0546.4 1036177	Novel Vectors and Genes Exhibiting Increased Expression	11/25/98 09/20/00	Pending	X
TTI-180HK	Hong Kong	I.R.C.	01 10 1652.6	Novel Vectors and Genes Exhibiting Increased Expression	03/07/01	Pending	X

Immune Response Corporation

TTL-180JP	Japan	I.R.C.	524420/00	Novel Vectors and Genes Exhibiting Increased Expression	11/25/98	Pending	X
TTL-200PC	PCT	I.R.C.	PCT/US01/05234	Methods and Compositions for Gene Delivery	02/16/01	Pending	X

TRADEMARKS

A. REMUNE - Worldwide Registrations and Pending Applications

1. REMUNE

Country: Argentina
Goods: Pharmaceuticals for the treatment of HIV, in Class 5.

App. Date: April 14, 1998
App. No.: N2.144.733
Status: Pending. Application opposed by Laboratorios Poen S.A.C.I.F.I., Laboratorios Elea S.A.C.I.F.A., and Renome S.A. Immune Response has executed Settlement Agreements with the opposing parties. Certificate of Registration will issue in due course.

2. REMUNE

Country: Australia
Goods: Pharmaceuticals for the treatment of HIV being goods in Class 5.

Reg. Date: April 8, 1998
Reg. No. 759257
Status: Registered April 8, 1998; Renewal due April 8, 2008.

3. REMUNE

Country: Brazil
Goods: Pharmaceuticals for the treatment of HIV, in Class 5.

App. Date: July 6, 1998
Reg. No.: 820887811
Status: Registered November 7, 2000. A Certificate of Registration will issue in due course.

4. REMUNE

Country: Canada
Goods: Pharmaceuticals for the treatment of HIV.

App. Date: April 15, 1998
App. No.: 875229
Status: Pending. Foreign Trademark office requires a Certified copy of the U.S. Registration by January 24, 2002 or an additional extension.

Immune Response Corporation

5. **REMUNE**

Country: CTM - European Union
Goods: Drug for treatment of HIV, in Class 5.

Reg. Date: April 1, 1996
Reg. No.: 480590
Status: Registered August 8, 1999; Renewal due April 1, 2006.

6. **REMUNE**

Country: Japan
Goods: Pharmaceuticals for the treatment of HIV, and other pharmaceuticals, in Class 5.

App. Date: April 8, 1998
Reg. No.: 4283555
Status: Registered June 11, 1999; Renewal due June 11, 2009.

7. **REMUNE**

Country: Mexico
Goods: Pharmaceuticals for the treatment of HIV, in Class 5.

App. Date: April 15, 1998
Reg. No.: 580883
Status: Registered June 30, 1998; Renewal due April 15, 2008.

8. **REMUNE**

Country: New Zealand
Goods: Pharmaceuticals for the treatment of HIV, in Class 5.

App. Date: August 10, 1998
Reg. No.: 296345
Status: Registered; Renewal due August 10, 2005.

9. **REMUNE**

Immune Response Corporation

Country: Thailand
Goods: Pharmaceutical for the treatment of HIV, in Class 5.

App. Date: September 9, 1998
Reg. No.: Kor91338
Status: Registered May 11, 1999; Renewal due September 8, 2008.

10. REMUNE

Country: United States
Goods: Pharmaceutical preparations for use in the treatment of HIV, in Class 5.

Reg. Date: June 26, 2001
Reg. No.: 2,464,045
Status: Registered; Declaration of Use due June 26, 2007.

B. Pending U.S. Applications

1. NEUROVAC

Goods: Pharmaceutical preparations for the treatment of multiple sclerosis, in Class 5.

RefNo.: 042040-0263110
App. Date: July 26, 2000
App. No.: 78-018,443
Status: Published for Opposition on March 27, 2001; Awaiting Notice of Allowance.

2. NEUROVAX

Goods: Pharmaceutical preparations for the treatment of multiple sclerosis, in Class 5.

RefNo.: 042040-0263109
App. Date: July 25, 2000
App. No.: 78-018,363
Status: Published for Opposition on March 20, 2001; Extension of Time to file opposition filed against mark on April 11, 2001; Opposition proceeding instituted on August 1, 2001 and is currently pending.

Immune Response Corporation

3. **RAVAC**

Goods: Pharmaceutical preparations namely a rheumatoid arthritis vaccine, in Class 5.

RefNo.: 042040-0263118

App. Date: July 27, 2000

App. No.: 78-018,710

Status: Published for Opposition on May 22, 2001; Extension of Time to file opposition filed against mark on June 14, 2001.
regard to this matter.

Please note that due to conflicts of interest, we cannot advise you with

4. **RAVAX**

Goods: Pharmaceutical preparations namely a rheumatoid arthritis vaccine, in Class 5.

RefNo.: 042040-0263118

App. Date: July 27, 2000

App. No.: 78-018,708

Status: Allowed: September 4, 2001
Notice of Allowance Issued; Statement of Use/First Request for Extension of Time due **March 4, 2001**.

5. **ZORCELL**

Goods: Pharmaceutical, namely, a drug for the treatment of psoriasis, in Class 5.

RefNo.: 042040-0260801

App. Date: April 14, 2000

App. No.: 78-004,228

Status: Published for Opposition on December 5, 2001; Extension of Time to file opposition filed against mark on January 4, 2001.

TRADEMARK

REEL: 002422 FRAME: 0862

RECORDED: 11/09/2001